DE-130 (STN-101)
Dry Eye Disease
Phase 2Active
Key Facts
About Santen Pharmaceutical
Santen's mission is to contribute to the well-being of patients, society, and employees by addressing ophthalmic diseases through specialized innovation. The company has achieved a leading global position in ophthalmology with a robust commercial portfolio and a deep R&D pipeline focused on glaucoma, retinal diseases, and ocular surface disorders. Its strategy is built on a vertically integrated, ophthalmology-focused model that enables deep expertise, operational efficiency, and targeted global expansion in both developed and emerging markets.
View full company profileTherapeutic Areas
Other Dry Eye Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Avarept® Ophthalmic suspension 0.3% | Senju Pharmaceutical | Approved |
| Dry Eye Care Portfolio | YD Bio | Commercial |
| Dry Eye Studies | Oculus Research | Not Applicable (Service Provider) |
| MediPrint Lens (Dry Eye) | MediPrint Ophthalmics | Pre-clinical/Research |
| MIEBO™ (perfluorohexyloctane) | Bausch + Lomb | Approved |
| Tivanisiran | Sylentis | Phase 2/3 |
| A197 | Aramis Biosciences | Phase 2 |
| KM102 | Theratome Bio | Pre-clinical |
| iTEAR®100 Commercialization | Olympic Ophthalmics | Commercial |
| HydraD | EyeD Pharma | Pre-Clinical |
| ST-100 (Vezocolmitide) | Stuart Therapeutics | Phase 3 |
| CyclASol® | Novaliq | Approved |